Alexandria Real Estate Equities

TFC Therapeutics is a biotechnology company focused on developing innovative biologics aimed at addressing key drivers of cancer recurrence and metastasis. The company’s technology utilizes monoclonal antibodies that specifically bind to receptors on the surface of tumor-initiating cells (TMH cells). This binding action activates the immune system to target and destroy these cells, offering the potential for new cancer treatments. By concentrating on the elimination of TMH cells, TFC Therapeutics seeks to provide effective solutions for improving patient outcomes in cancer care.

Stablix Therapeutics is a biotechnology company specializing in Targeted Protein Stabilization (TPS). The company has developed a platform that produces heterobifunctional small molecules, known as RESTORACS, which selectively recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins. This process enhances the stability and activity of these proteins. Stablix focuses on utilizing its innovative technology to create therapeutic programs aimed at treating rare diseases, cancer, and immunological disorders. By restoring protein function, Stablix aims to provide more effective treatment options for complex medical conditions.

C2i Genomics, Inc. specializes in whole genome analysis solutions aimed at monitoring tumor recurrence in post-surgery cancer patients. The company offers liquid biopsy services that analyze subtle changes in tumor DNA to provide insights into cancer progression and recurrence. This technology enables the development of a bio-platform approach applicable across various cancer types, facilitating the guidance of diverse treatment modalities, including surgery, chemotherapy, immunotherapy, and targeted therapies. Additionally, C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations, enhancing the ability of healthcare providers to monitor treatment responses and detect recurrences or failures earlier than traditional methods allow. Founded in 2019 and headquartered in New York, with a research and development center in Haifa, Israel, C2i Genomics aims to improve the lives and outcomes of cancer patients through innovative diagnostic solutions.

TerMir is an AgTech company focused on providing innovative solutions to significant agronomic and environmental challenges. The company develops antibacterial agents specifically aimed at treating invasive citrus greening disease, a major threat to citrus crops. Additionally, TerMir offers biological herbicides that help control weed growth, thereby enhancing crop production for farmers. By addressing these critical issues, TerMir aims to support sustainable agricultural practices and improve the overall efficiency of farming operations.

Cradle Genomics, Inc. specializes in fetal genetic analysis and pregnancy health screening solutions, focusing on non-invasive prenatal testing (NIPT) to provide comprehensive insights at the earliest stages of pregnancy. Founded in 2018 and headquartered in San Diego, California, with research and development operations in Detroit, Michigan, the company has developed a platform that analyzes genetic material from fetal cells collected during a first trimester visit. This approach allows pregnant women to receive critical information about their health and the health of their developing fetus without any risk. Cradle Genomics aims to empower expectant parents with knowledge that can guide their decisions throughout the pregnancy journey.

Strand Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2017. The company focuses on genetically programming mRNA to develop innovative therapies that enhance patient outcomes. Utilizing its mRNA programming technology, Strand Therapeutics creates gene therapies powered by synthetic biology, which include immunotherapies designed to stimulate cells to produce cancer-targeting proteins. This approach improves the immune system's ability to combat cancer by enabling precise control over the timing, location, and intensity of therapeutic protein expression. The technology leverages cell-type specific expression and responds to specific molecular signals, allowing for tailored therapeutic interventions.

Halio specializes in advanced smart-tinting glass that adapts to changing light conditions, enhancing architectural design and efficiency. Its innovative technology allows the glass to transition from clear to tinted or dark in seconds, providing shade, glare relief, and privacy as needed. Unlike traditional electrochromic glass, Halio's product offers uniform tinting without undesirable hues, achieving a natural glass appearance in various neutral shades. The company also provides sophisticated software and hardware controls that integrate seamlessly with building management systems. Halio’s manufacturing process ensures high yields akin to the flat panel display industry, allowing for reliable and timely deliveries worldwide. This transformative glass not only improves the comfort and aesthetics of buildings but also fosters a deeper connection between indoor environments and the outside world.

Avidity Biosciences, Inc. is a biotechnology company focused on developing oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These innovative therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. This approach allows Avidity to target previously undruggable tissue and cell types, thereby addressing the underlying genetic drivers of various diseases. The company's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare muscle disease. Additionally, Avidity is advancing multiple programs aimed at treating muscle-related conditions such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Founded in 2012 and based in La Jolla, California, Avidity is also exploring therapeutic applications in immune and other cell types.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

Aitia specializes in applying Causal AI and Digital Twins to advance drug discovery and development. The company utilizes multi-omic patient data and high-performance computing to uncover the underlying biological mechanisms of diseases, creating Digital Twins for conditions such as oncology, neurodegenerative disorders, and immunology. Their Gemini Digital Twins are actively employed to explore new therapies and expedite research and development in areas like multiple myeloma, prostate cancer, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease, with additional projects in the pipeline. Aitia collaborates with seven of the top ten pharmaceutical companies, academic research institutions, medical societies, multi-omic data firms, and patient advocacy organizations, positioning itself as a leader in the innovative intersection of technology and healthcare.

Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.

Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, that aims to repair or reverse damage from various degenerative diseases by utilizing the body’s own biological mechanisms. The company employs a Progenitor Cell Activation approach, which involves the use of small molecules to activate progenitor cells and promote the regeneration of functional tissue. Its leading product candidate, FX-322, is currently undergoing phase 2a clinical trials to address the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is also exploring treatments for a range of other conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. The company has established a collaboration with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics focuses on disease modification without the complexities associated with genetic engineering.

GenePeeks, Inc. is a genetic information company headquartered in New York, New York, that focuses on reducing the risk of heritable diseases through innovative technology. Incorporated in 2009, the company has developed a proprietary software platform that digitally combines the DNA of prospective parents to simulate genetic recombination and reduction. This process generates a comprehensive analysis of potential future children’s genetic profiles, identifying disease risks that existing pre-conception screening methods may overlook. By utilizing Next-Gen sequencing data, GenePeeks creates tens of thousands of virtual genomes, enabling healthcare providers to assess high-risk genetic matches and enhance their understanding of clinically relevant genotypes and variants. The company's mission is to help families safeguard the health of future generations by providing deeper genetic insights.

AgriMetis, LLC is engaged in the research, development, and production of crop protection products, specifically focusing on fungicides, herbicides, insecticides, and nematicides derived from natural sources. Founded in 2014, the company is headquartered in Lutherville, Maryland, with additional facilities in Research Triangle Park, North Carolina, and a laboratory in Gaithersburg, Maryland. AgriMetis aims to provide sustainable and effective solutions for protecting crops from weeds, fungal diseases, and insect pests, offering farmers safe and cost-effective options for crop management. Its innovative approach combines natural product-derived compounds with advanced production processes to address the challenges faced in agricultural protection.

Blackthorn Therapeutics, based in South San Francisco, California, is a clinical-stage biopharmaceutical company focused on developing precision medicine for neurobehavioral disorders. Founded in 2013, the company utilizes a proprietary computational platform that integrates advances in computational and clinical neuroscience to better understand the relationship between brain function and behavior. By targeting dysfunctional brain circuits, Blackthorn aims to address longstanding challenges in drug discovery and development. The company’s approach involves identifying novel therapeutic targets, small molecule drug candidates, and biologically-based patient subgroups that are most likely to benefit from treatment, thereby enhancing the precision of therapeutic interventions in the central nervous system.

OncoResponse Inc. is an immuno-oncology biotechnology company based in Houston, Texas, focused on developing innovative cancer therapies. The company utilizes a proprietary human antibody platform to identify fully human monoclonal antibodies targeting immuno-oncology pathways. By probing the adaptive immune systems of cancer patients who have shown exceptional responses to checkpoint inhibitors, OncoResponse aims to discover novel therapeutic antibodies. Its research emphasizes addressing immunosuppressive myeloid biology and enhancing immune activation, with the goal of transforming cold tumors into hot tumors that are more responsive to treatment. Through its advanced antibody pipeline, OncoResponse is dedicated to providing effective solutions for cancer treatment.

IDEAYA Biosciences is an oncology-focused biotechnology company based in South San Francisco, California, dedicated to the discovery and development of targeted therapeutics for genetically defined patient populations. The company specializes in precision medicine using molecular diagnostics and synthetic lethality approaches to address cancer treatment. Its lead product candidate, IDE196, is a protein kinase C inhibitor currently undergoing Phase 1/2 clinical trials for cancers associated with GNAQ or GNA11 gene mutations. IDEAYA's preclinical pipeline includes programs targeting various mechanisms related to DNA damage and repair, such as MAT2A for tumors with MTAP deletions, Pol-theta for homologous recombination deficiency, and PARG for BRCA2 mutation context. The company collaborates with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase, while also engaging in partnerships for clinical trials with Pfizer and GlaxoSmithKline. Founded in 2015, IDEAYA aims to advance innovative therapies for enhancing immunotherapy responses and improving patient outcomes in oncology.

Aitia specializes in applying Causal AI and Digital Twins to advance drug discovery and development. The company utilizes multi-omic patient data and high-performance computing to uncover the underlying biological mechanisms of diseases, creating Digital Twins for conditions such as oncology, neurodegenerative disorders, and immunology. Their Gemini Digital Twins are actively employed to explore new therapies and expedite research and development in areas like multiple myeloma, prostate cancer, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease, with additional projects in the pipeline. Aitia collaborates with seven of the top ten pharmaceutical companies, academic research institutions, medical societies, multi-omic data firms, and patient advocacy organizations, positioning itself as a leader in the innovative intersection of technology and healthcare.

Faraday Pharmaceuticals, Inc. is a biopharmaceutical company based in Seattle, Washington, that focuses on developing innovative therapies to treat ischemia-reperfusion injury, particularly following ST elevation myocardial infarction. Founded in 2014, the company has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements, which were developed in the laboratory of Dr. Mark Roth at the Fred Hutchinson Cancer Center. Faraday's therapeutics aim to utilize specific reduced forms of elements to enhance patient outcomes, providing medical practitioners with effective treatment options for ischemia-reperfusion injury and other critical care conditions.

Cydan is an orphan drug accelerator focused on developing therapies for patients with rare genetic diseases. The organization identifies and mitigates the risks associated with compounds that have therapeutic and commercial potential. Through a rigorous process, Cydan generates data to support the development of new therapies and the formation of new companies. Their experienced team leverages strong relationships with academia and patient advocacy groups, along with deep expertise in drug development and a proven track record of successful product commercialization. By guiding therapies through clinical, regulatory, and commercial development, Cydan aims to improve the lives of patients and families affected by rare diseases.

Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.

Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.

Oncofactor is a Seattle, Washington-based developer of cancer therapeutics that disrupt signaling pathways between tumors and the immune system.

Acylin Therapeutics is the first company focused on developing inhibitors of cellular acetylation, an enzymatic mechanism fundamental to the molecular pathology of cancer, metabolic disease, and neurodegeneration. Recent discoveries by Acylin founders and other investigators have revealed protein acetylation as a cellular signal transduction regulator potentially as ubiquitous and important as phosphorylation by kinase enzymes. The Company has developed a platform technology to design specific acyltransferase inhibitors based on crystal structures, novel medicinal chemical approaches, and mechanistic understanding. Acylin has prioritized the p300 and CBP histone acetyl transferases [HATs] for initial drug discovery.

Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.

Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

BrainCells develops and provides biopharmaceutical products for the treatment of central nervous system (CNS) diseases. It develops compounds that promote the growth of new neurons for the treatment of major depressive disorder (MDD), treatment resistant depression (TRD), and potentially Alzheimer’s disease (AD). The company's products include BCI-838 and BCI-632 which increase synaptic glutamate by inhibiting the mGlu2/3 auto-receptor. The company also builds a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes, and other CNS disorders. The company was founded in 2003 and is based in San Diego, California.

Cerulean Pharma Inc. is a privately-held biopharmaceutical company specializing in the development of innovative nanotechnology-based therapeutics aimed at treating oncology, cardiovascular, autoimmune, and inflammatory diseases. The company focuses on nanoparticle-drug conjugates that target tumors, reduce toxicity, and facilitate therapeutic combinations. Among its notable products is Ovaprene, a contraceptive designed to offer hormone-free protection for multiple weeks. Cerulean has established a distinguished management team and advisory board, drawing from extensive experience in product development and scientific innovation from renowned institutions and companies in the biopharmaceutical sector.

Allozyne, Inc. is a biopharmaceutical company based in Seattle, Washington, focused on developing innovative protein therapeutic candidates for autoimmune and inflammatory diseases, as well as cancer. Its lead product candidate, AZ01, is currently in a Phase 1b clinical trial aimed at treating relapsing-remitting multiple sclerosis. The company is also advancing AZ17, a bispecific antibody designed for various autoimmune and inflammatory conditions, including Crohn's disease and multiple sclerosis, and AZ05, an antibody-drug conjugate targeting solid tumors. Founded in 2004, Allozyne is dedicated to enhancing the efficacy, safety, and dosing of protein-based therapeutics, including peptides and antibodies. It operates as a subsidiary of Poniard Pharmaceuticals, Inc.

Accelerator Corporation, founded in 2003 and based in Seattle, Washington, is a venture capital firm that specializes in early-stage investments in biotechnology companies. The firm primarily invests up to $2 million in emerging growth and start-up ventures, focusing on identifying, evaluating, financing, and managing groundbreaking life sciences opportunities. Accelerator does not participate in subsequent financing rounds and typically maintains its investments for 12 to 24 months. The firm has developed a robust pipeline of deal flow through partnerships with top-tier investors and research institutions, providing access to state-of-the-art facilities and expertise in scientific and technical support. Over the past five years, Accelerator has invested in nine companies, three of which successfully raised follow-on financing exceeding $114 million. In total, Accelerator's portfolio companies have garnered over $143.5 million in initial and follow-on funding, supported by an additional commitment of $22.5 million from investors to further pursue innovative biotechnology opportunities. Through its unique resources and collaborations, Accelerator is positioned to streamline the development and commercialization of novel technologies in the biotechnology sector.

BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.

Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.

Magen BioSciences is a biotechnology company based in Waltham, Massachusetts, focused on developing pharmaceutical products aimed at enhancing human skin health. Utilizing a science-driven approach, the company leverages its comprehensive understanding of both normal and diseased skin biology to create solutions that improve the health and appearance of the skin.

Map Pharmaceuticals, Inc. is a development-stage company based in Mountain View, California, specializing in the creation of novel inhalation therapies for respiratory and systemic diseases. Founded in 2003, the company is advancing several proprietary product candidates through clinical development. These include Unit Dose Budesonide, aimed at treating pediatric asthma in children aged six months to eight years, and MAP0004, designed for migraine relief. Additionally, Map Pharmaceuticals is developing MAP0005 for adolescent and adult asthma and chronic obstructive pulmonary disease, as well as MAP0001, which targets Type 1 and Type 2 diabetes through pulmonary delivery via its Tempo inhaler. The company's focus is on delivering innovative treatments to improve patient outcomes across various health conditions.

Hypnion is a neuroscience drug discovery and development company that specializes in creating innovative therapeutics for central nervous system disorders, particularly focusing on sleep and wake-alertness issues as well as circadian rhythm abnormalities. Founded in 2000 and based in Worcester, Massachusetts, Hypnion has developed a proprietary drug discovery platform known as SCORE-2004, which measures the effects of various drugs on sleep and wake parameters. The company has attracted attention in the pharmaceutical industry, culminating in its acquisition by Eli Lilly and Company.

Integrated Diagnostics Inc. specializes in the development of laboratory-based blood molecular diagnostic tools designed to assist physicians in the early detection of complex diseases through non-invasive blood tests. The company's flagship product, Xpresys Lung, provides objective information for assessing pulmonary nodules by monitoring multiple disease molecular markers simultaneously. Founded in 2005 and based in Seattle, Washington, Integrated Diagnostics aims to leverage emerging technologies to create a pipeline of innovative diagnostic products that facilitate the management of serious conditions such as cancer, diabetes, and Alzheimer's. The company operates under the principle that a systems view of disease, involving networks of proteins, genes, and other molecules, is essential for effective diagnosis and prognosis. Integrated Diagnostics is a subsidiary of Biodesix, Inc. and has established a strategic partnership with Agilent Technologies.

Accelerator Corporation, founded in 2003 and based in Seattle, Washington, is a venture capital firm that specializes in early-stage investments in biotechnology companies. The firm primarily invests up to $2 million in emerging growth and start-up ventures, focusing on identifying, evaluating, financing, and managing groundbreaking life sciences opportunities. Accelerator does not participate in subsequent financing rounds and typically maintains its investments for 12 to 24 months. The firm has developed a robust pipeline of deal flow through partnerships with top-tier investors and research institutions, providing access to state-of-the-art facilities and expertise in scientific and technical support. Over the past five years, Accelerator has invested in nine companies, three of which successfully raised follow-on financing exceeding $114 million. In total, Accelerator's portfolio companies have garnered over $143.5 million in initial and follow-on funding, supported by an additional commitment of $22.5 million from investors to further pursue innovative biotechnology opportunities. Through its unique resources and collaborations, Accelerator is positioned to streamline the development and commercialization of novel technologies in the biotechnology sector.

Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.

Accelerator Corporation, founded in 2003 and based in Seattle, Washington, is a venture capital firm that specializes in early-stage investments in biotechnology companies. The firm primarily invests up to $2 million in emerging growth and start-up ventures, focusing on identifying, evaluating, financing, and managing groundbreaking life sciences opportunities. Accelerator does not participate in subsequent financing rounds and typically maintains its investments for 12 to 24 months. The firm has developed a robust pipeline of deal flow through partnerships with top-tier investors and research institutions, providing access to state-of-the-art facilities and expertise in scientific and technical support. Over the past five years, Accelerator has invested in nine companies, three of which successfully raised follow-on financing exceeding $114 million. In total, Accelerator's portfolio companies have garnered over $143.5 million in initial and follow-on funding, supported by an additional commitment of $22.5 million from investors to further pursue innovative biotechnology opportunities. Through its unique resources and collaborations, Accelerator is positioned to streamline the development and commercialization of novel technologies in the biotechnology sector.

Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.

MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, specializing in the discovery and development of antibody-based therapeutics for cancer treatment. Founded in 2000, the company focuses on immuno-oncology and has a diverse pipeline of product candidates. Key developments include Margetuximab, a monoclonal antibody in Phase III clinical trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other investigational products include MGA012, MGD013, MGD019, and Enoblituzumab, which target various immune checkpoints and tumor-associated antigens. MacroGenics is also advancing combination therapies and antibody-drug conjugates, such as MGC018, which targets solid tumors expressing B7-H3. The company has formed strategic collaborations with notable partners, enhancing its research and development efforts in the biopharmaceutical landscape.

Nanosys, Inc. is a company that specializes in the development and manufacturing of quantum dot technology aimed at enhancing high-definition viewing experiences across various display applications. Founded in 2001 and headquartered in Milpitas, California, Nanosys produces Quantum Dot Concentrate materials and Quantum Dot Enhancement films that improve the performance of a wide range of consumer electronics, including televisions, tablets, and smartphones. The company's quantum dots are nanoscale semiconductors that enable displays to achieve greater brightness and a wider color gamut, resulting in more lifelike images. This technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs. Nanosys has seen significant adoption of its technology, with over 20 million devices shipped in numerous products, thus contributing to advancements in the display industry.

Norak Biosciences, Inc., headquartered in Research Triangle Park, NC, is a private biotechnology company. Norak is utilizing its proprietary Transfluor technology to become a world leader in the discovery and development of drugs that regulate G protein-coupled receptors.

Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.

GoAhead Software, Inc. specializes in integrated middleware solutions tailored for telecom, military, and aerospace equipment manufacturers. The company provides a range of products, including SelfReliant, which ensures high availability and effective systems management, and the Application Ready Platform, which facilitates resource discovery, system model instantiation, shelf manager integration, alarm management, and hot swap management. Additionally, GoAhead offers an open-source Web server designed for embedded device developers, supporting features such as active server pages and user management. The company's software solutions cater to various development projects, including wireless base station controllers, defense applications, and industrial controllers. Founded in 1993, GoAhead is headquartered in Bellevue, Washington.